Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study-NCCTG trial N00CB

Journal of Supportive Oncology

Volumn 8, Issue 3, 2010, Pages 128-132

  Moraska, Amanda R ^a   Atherton, Pamela J ^b   Szydlo, Daniel W ^c   Barton, Debra L ^d   Stella, Philip J ^e   Rowland Jr , Kendrith M ^f   Schaefer, Paul L ^g   Krook, James ^h   Bearden III, James D ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b Metro Minnesota Community Clinical Oncology Program   (United States)

^c Michigan Cancer Research Consortium   (United States)

^d Carle Cancer Center CCOP   (United States)

^e Toledo Community Hospital Oncology Program   (United States)

^f Duluth CCOP   (United States)

^g Upstate Carolina CCOP   (United States)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PLACEBO; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

AGED; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ARTICLE; CANCER SURVIVOR; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; HOT FLUSH; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; OPEN STUDY; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; SURVIVOR;

AGED; AMINES; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; GAMMA-AMINOBUTYRIC ACID; HOT FLASHES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVORS;

EID: 77954059217     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Schow DA, Renfer LG, Rozanski TA, et al. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998;91:855-857. [9743058]
2. Charig CR, Rundle JS. Flushing. Longterm side effect of orchiectomy in treatment of prostatic carcinoma. Urology 1989;33:175-178. [24656244]
3. Clark JA, Wray N, Brody B, et al. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med 1997;45:1299-1309. [9381242]
4. Loprinzi C, Goldberg RM, O'Fallon JR, et al. Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol 1993;151:634-636. [8308973]
5. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-352. [8028614]
6. Atala A, Amin M, Harty JI. Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle- stimulating hormone, luteinizing hormone, and testosterone. Urology 1992;39:108-110. [1736500]
7. Burch PA, Loprinzi CL. Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate. J Clin Oncol 1999;17:1087- 1088. [10071307]
8. Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162:98- 102. [10379749]
9. Loprinzi CL, Barton DL, Carpenter LA, et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 2004;79:1247- 1251. [15473404]
10. Loprinzi CL, Dueck AC, Khoyratty BS, et al. A phase III randomized, double-blind, placebocontrolled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 2009;20:542-549. [19129205]
11. McNair DM, Loor M, Droppleman LF. Profile of Mood States Manual. New York, NY: Multi-Health Systems; 2003.
12. Quella S, Loprinzi CL, Dose AM. A qualitative approach to defining "hot flashes" in men. Urol Nurs 1994;14:155-158. [7817208]
13. Guttuso T Jr, Kurlan R, McDermott MP, et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-345. [12576259]